iADCs are a next-generation modality for treating cancer and designed to boost anti-cancer activity, offering potential new options for patients who do not respond to existing cancer immunotherapies -
- Sutro will receive an upfront payment of US$90 million to develop iADCs for three biological targets and may be eligible to receive up to an additional US$422.5 million USD in development, regulatory and commercial milestones for each product candidate, plus royalties -
https://finance.yahoo.com/news/astellas-sutro-biopharma-announce-worldwide-233100535.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.